Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

With lower threat of resistance it would become standard of care even if only equal to in efficacy. The resistance issue is huge.

Single dosage would be quite the bonus.






In Reply to 'noretreat'
I am thinking that to become the standard of care, B needs to be "non-inferior" to daptomycin. Then the extra benefits of single dose, lower resistance and lower threat of resistance really can multiply the potential. I am optimistic about the trial, but it is not without risk.

Wild-I don't think there have been any changes made to B for this trial besides dosage level and frequency...